Squamous Cell Carcinoma of the Head and Neck
📧 Sign up to get email alerts when something new happens for Squamous Cell Carcinoma of the Head and Neck.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
-
EMA approval · 2026-04-22EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
FDA approval · 2018-06-05FDA Approved: ERBITUX — Supplemental Application (ImClone LLC)
The FDA approved a supplemental application for ERBITUX (cetuximab) filed by ImClone LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-10-11FDA Approved: ERBITUX — Supplemental Application (ImClone LLC)
The FDA approves a supplemental application for Erbitux (cetuximab) filed by ImClone LLC.